United Therapeutics Q4 revenue growth falls short of analyst expectations

United Therapeutics

25/02/2026 11:41

Overview

Biotech firm's Q4 revenue missed analyst expectations

Net income for Q4 rises compared to last year

Company repurchased $1 bln of common stock in August 2025

Outlook

United Therapeutics anticipates pivotal data from ADVANCE OUTCOMES and TETON-1 trials

Company expects continued double-digit revenue growth

Result Drivers

TYVASO DPI GROWTH - Significant revenue growth driven by increased sales of Tyvaso DPI, attributed to more patients and Medicare Part D benefit redesign

ORENITRAM SALES INCREASE - Orenitram revenues grew due to increased quantities sold, influenced by Medicare Part D benefit redesign

NEBULIZED TYVASO DECLINE - Decline in Nebulized Tyvaso sales due to decreased quantities sold

Company press release: ID:nBw6YsyZLa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$790.20 mln
$813.08 mln (11 Analysts)
Q4 EPS
$7.70
Q4 Net Income
$364.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for United Therapeutics Corp is $525.00, about 10.9% above its February 24 closing price of $473.43

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)